Hubei Jumpcan Pharmaceutical (600566) Stock Overview
Engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based Chinese traditional medicines, and Chinese medicine health products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
600566 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Hubei Jumpcan Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥26.32 |
| 52 Week High | CN¥34.46 |
| 52 Week Low | CN¥23.85 |
| Beta | 0.075 |
| 1 Month Change | -4.33% |
| 3 Month Change | -0.11% |
| 1 Year Change | -18.29% |
| 3 Year Change | 4.86% |
| 5 Year Change | -2.88% |
| Change since IPO | 32.86% |
Recent News & Updates
Recent updates
Is Hubei Jumpcan Pharmaceutical (SHSE:600566) Using Too Much Debt?
Mar 19
Hubei Jumpcan Pharmaceutical (SHSE:600566) Ticks All The Boxes When It Comes To Earnings Growth
Jan 27Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Prospects Need A Boost To Lift Shares
Dec 31Does Hubei Jumpcan Pharmaceutical (SHSE:600566) Have A Healthy Balance Sheet?
Dec 10Why Investors Shouldn't Be Surprised By Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) 26% Share Price Plunge
Sep 11An Intrinsic Calculation For Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) Suggests It's 45% Undervalued
Sep 09Is Hubei Jumpcan Pharmaceutical (SHSE:600566) A Risky Investment?
Aug 07Is Now The Time To Put Hubei Jumpcan Pharmaceutical (SHSE:600566) On Your Watchlist?
Jul 01Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Prospects Need A Boost To Lift Shares
May 30Hubei Jumpcan Pharmaceutical (SHSE:600566) Ticks All The Boxes When It Comes To Earnings Growth
Mar 17Shareholder Returns
| 600566 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.7% | 3.0% | 1.8% |
| 1Y | -18.3% | 27.5% | 25.6% |
Return vs Industry: 600566 underperformed the CN Pharmaceuticals industry which returned 27.5% over the past year.
Return vs Market: 600566 underperformed the CN Market which returned 25.6% over the past year.
Price Volatility
| 600566 volatility | |
|---|---|
| 600566 Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in CN Market | 8.5% |
| 10% least volatile stocks in CN Market | 2.8% |
Stable Share Price: 600566 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600566's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 5,026 | Fei Cao | www.jumpcan.com |
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based Chinese traditional medicines, and Chinese medicine health products in China. The company offers Chinese and western medicines in the areas of pediatrics, gynecology, pneumology, gastroenterology, neurology, and geriatrics; oral and skin care products; and anti-fatigue, anti-aging, antioxidant, and immunity-enhancing Chinese medicine health products. It also develops Chinese and western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis.
Hubei Jumpcan Pharmaceutical Co., Ltd. Fundamentals Summary
| 600566 fundamental statistics | |
|---|---|
| Market cap | CN¥24.24b |
| Earnings (TTM) | CN¥2.13b |
| Revenue (TTM) | CN¥7.14b |
Is 600566 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600566 income statement (TTM) | |
|---|---|
| Revenue | CN¥7.14b |
| Cost of Revenue | CN¥1.56b |
| Gross Profit | CN¥5.58b |
| Other Expenses | CN¥3.45b |
| Earnings | CN¥2.13b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 23, 2025
| Earnings per share (EPS) | 2.31 |
| Gross Margin | 78.15% |
| Net Profit Margin | 29.79% |
| Debt/Equity Ratio | 4.6% |
How did 600566 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/15 08:29 |
| End of Day Share Price | 2025/07/15 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hubei Jumpcan Pharmaceutical Co., Ltd. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bin Wu | China Merchants Securities Co. Ltd. |
| Lan Lan | Founder Securities Co., Ltd. |
| Wen Dai | Huatai Research |